INTRODUCTION
============

T-regulatory cells (Tregs) are a suppressive subset of T cells, which make up around 10% of CD4^+^ cells, crucial to the proper maintenance of immune self-tolerance and homeostasis. Natural Tregs are produced in the thymus but some Tregs may also be induced in the periphery ([@B42]). Since the discovery that CD25-expressing T cells in the normal immune system have suppressive function ([@B39]), the field of regulatory T cells has advanced with the discovery that the transcription factor Foxp3 is critical to the suppressive function of Tregs as illustrated by the finding that ectopic expression of Foxp3 can induce regulatory function in naïve T cells ([@B17]; [@B22]). A loss of Foxp3 function results in Treg deficiency or dysfunction and is responsible for the autoimmune disorders seen in both Scurfy mice ([@B4]; [@B25]) and the human immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) syndrome ([@B54]). Foxp3 regulates expression of a large number of genes including those responsible for key features of Tregs, such as an absence of IL-2 production and high expression of cytotoxic T lymphocyte antigen-4 (CTLA-4) and CD25. While it has been clear for some time that Tregs are critical to the maintenance of immune self-tolerance and homeostasis, the exact mechanisms by which they are able to do this has been a source of considerable debate ([@B38]; [@B41]; [@B46]).

CORE MECHANISMS OF Treg SUPPRESSION
===================================

A number of different Treg suppressive mechanisms have been proposed. It seems that in part this is due to Tregs being able to adapt to environmental cues and alter their suppressive mechanisms to fit the circumstances. However, while there is some heterogeneity of function, all Foxp3-expressing Tregs may share a set of core suppressive mechanisms. As discussed below, CTLA-4 and IL-2 are most stably activated or repressed, respectively, by Foxp3 and appear to be involved in such core mechanisms.

CTLA-4-DEPENDENT SUPPRESSION
============================

CTLA-4 is constitutively expressed by Foxp3^+^ Tregs and competes with the closely related CD28 for binding with the co-stimulatory molecules, CD80 and CD86, on the surface of APCs. While CTLA-4 is also expressed on activated T-effector cells, mice with a Treg specific CTLA-4 depletion suffer from fatal lymphoproliferative disease, similar to that seen in totally CTLA-4-deficient mice, despite the development of Tregs in normal numbers ([@B52]; [@B56]). CTLA-4-deficient Tregs also show impaired *in vitro* suppressive activity ([@B56]), while mice with mixed bone marrow chimeras of CTLA-4-deficient and sufficient donors do not develop autoimmune disease, demonstrating cell extrinsic function ([@B1]). For some time the mechanisms of CTLA-4 function have been obscure but recent work has elegantly demonstrated that CTLA-4-mediated trans-endocytosis and degradation of CD80/86 from the surface of APCs is a key mechanism of CTLA-4 function ([@B35]). However, this may not be the sole mechanism of CTLA-4 function as CTLA-4 ligation of CD80/86 also induces nuclear translocation of the transcription factor Foxo3 inhibiting dendritic cell (DC) expression of IL-6 and TNFα, while Foxo3 KO mice have enhanced CD80/86 expression ([@B14]). In addition, CTLA-4 engagement may cause DCs to express the immunosuppressive tryptophan catabolizing enzyme IDO ([@B19]). These findings collectively suggest that CTLA-4 is critical to the suppressive function of Tregs and appears to act primarily via cell extrinsic effects on APCs ([@B56]) in which Treg expression of CTLA-4 reduces APC expression of CD80 and 86 thus reducing their co-stimulatory capacity ([@B57]).

IL-2-DEPENDENT SUPPRESSION
==========================

Several cardinal features of Foxp3^+^ Tregs are their absence of IL-2 production, constitutively high expression of the alpha chain receptor for IL-2 (CD25) and consequent ability to bind IL-2 with high affinity ([@B40]). A central role for IL-2 in Treg biology has been demonstrated by *in vivo* studies of mice either deficient in IL-2 production ([@B44]) or IL-2 receptor ([@B47];[@B55]): both suffer from fatal lymphoproliferative disease in a manner similar to Foxp3-deficient scurfy mice. Tregs are able to suppress both IL-2 mRNA and protein production by responder T cells ([@B48]; [@B49]), most likely indirectly due to a CTLA-4-mediated reduction in CD80/86 co-stimulation from APCs and also consume IL-2, thus denying it to local T-effector cells ([@B13]). This may in turn lead to arrest of proliferation and apoptosis of T-effector cells ([@B34]). Since Tregs are dependent on exogenous IL-2 for their survival and function ([@B18]; [@B45]) but suppress its production by T cells, it seems that IL-2 is used as a feedback mechanism to prevent Treg overgrowth that might otherwise result in excessive immunosuppression.

Foxp3 regulated features of Treg biology such as high expression of CTLA-4, CD25 and an absence of IL-2 production are critical to the function of Tregs, efficiently controlling APC-dependent activation and proliferation of T cells. As a result, knockout of either CTLA-4 or CD25 expression replicates the phenotype of Foxp3-deficient mice. However, in addition to this "core module" of suppression, Foxp3^+^ Tregs are also able to adapt to their environment and take on additional suppressive functions in order to fit the immune context they find themselves in. This may be of particular importance in the more inflammatory conditions found at barrier sites such as the gut in which CTLA-4 and IL-2-based suppression may be sometimes overwhelmed due to an excess of inflammatory signals leading to a requirement for additional mechanisms such as IL-10 ([@B37]; [@B60]).

ADAPTABILITY OF SUPPRESSIVE MECHANISMS AND INDUCTION OF ADDITIONAL TRANSCRIPTION FACTORS
========================================================================================

CTLA-4-dependent suppression is not the only mechanism by which Tregs are able to suppress the activity of other cells. *In vitro* experiments give a clear indication of this: while normal Tregs suppress T-effector proliferation in a CTLA-4-dependent manner, Tregs derived from total CTLA-4-deficient mice also retain *in vitro* suppressive capacity. In this case it seems likely that Tregs derived from CTLA-4-deficient mice are highly activated due to the ongoing autoimmune pathology and as such may have induced suppressive functions such as IL-10 and TGFβ secretion. A wide range of other suppressive molecules have been identified in Tregs including: IL-10, TGFβ, Galectin, Neuropilin, IL-35, cAMP, Granzyme-B, perforin, and cAMP ([@B41]; [@B46]). Many of these molecules are upregulated in effector CD44^high^ Tregs.

In addition to adopting an effector phenotype in response to stimulation, recent work has demonstrated that Tregs are able to adapt to environmental signals and further differentiate from their base state by expression of transcription factors normally associated with other T cell subsets ([@B7]). It seems likely that Tregs share much of the same molecular machinery as conventional CD4^+^ T cells and respond to the same differentiation stimuli. This induction/co-opting of additional transcription factors seems to be critical to Treg suppression of particular T cell subsets and their associated immunopathology.

T-bet -- Th1
============

[@B26] have demonstrated that the transcription factor T-bet, normally required for the linage development of Th1 cells, is upregulated in Tregs in response to IFNγ, suggesting that the induction of this Treg subset occurs in reaction to a Th1 immune response ([@B26]). T-bet causes the Th1-associated chemokine receptor CXCR3 to be upregulated on the surface of Tregs and a small increase in IFNγ expression was also observed. CXCR3 homes the cell to the sites of Th1 inflammation via its IFNγ-induced ligands CXCL9, CXCL10, and CXCL11, allowing Tregs to provide *in situ* suppression. T-bet-deficient Tregs are unable to accumulate at the sites of Th1 inflammation and properly control the Th1 immune response ([@B26]). In addition, T-bet-deficient Tregs retain their *in vitro* suppressive activity ([@B3]) and *in vivo* have only a modest (approximately 50%) reduction in mRNA expression of the effector molecules, IL-10 and TGFβ ([@B26]). This suggests that the primary role of T-bet in Treg suppression of Th1 responses may be the control of CXCR3 expression and Treg localization.

IRF4 AND GATA-3 -- Th2
======================

The transcription factor interferon regulatory factor 4 (IRF4) is critical for the differentiation of Th2 cells and may also play a role in the differentiation of Th17 cells ([@B29]; [@B5]). Foxp3 is able to bind to the promoter region of IRF4 and enhance its expression ([@B62]). Additionally, Treg-specific deletion of *Irf4* prevents Tregs from efficiently suppressing Th2 immune responses leading to an uncontrolled Th2 immune response characterized by significantly enhanced IL-4 and IL-5 production, but not IFNγ, IL-2, or IL-17 ([@B62]). Additionally, IRF4-deficient Tregs have decreased expression of the genes encoding the suppressive molecules IL-10 and Granzyme B, while also reducing CCR8 expression, the chemokine receptor important for migration to the sites of Th2 inflammation ([@B62]).

[@B11] demonstrated a wider role for IRF4 expression with the finding that IRF4 may also be required for T-bet and Blimp-1 expression. Blimp-1 is a transcriptional repressor normally associated with plasma cell differentiation, but in Tregs it appears to be crucial to the expression of IL-10 ([@B11]). This would suggest that IRF4 expression by Tregs may also be critical to IL-10-dependent effector mechanisms. As a result it seems likely that part of the reason for the failure of IRF4-deficient Tregs to regulate Th2 responses may be due to a lack of IL-10 production.

It has also become clear that the canonical Th2 transcription factor, GATA-3, may also expressed by Tregs ([@B6]; [@B51]; [@B58]). In GATA-3-deficient Tregs, expression of Foxp3 and constitutively expressed Treg markers/effector molecules such as CLTA-4, GITR, and CD25 were all reduced both at the mRNA and protein levels. GATA-3-deficient Tregs are unable to prevent the induction of systemic lymphoproliferative disease and increased production of Th1, Th2, and Th17 cytokines ([@B51]). Thus, unlike STAT3 and T-bet, whose expression in Tregs appears to be largely linked to the control of the T cell subtypes with which they are associated, it seems that GATA-3 has a wider function in the maintenance of immunity. This is perhaps not surprising as while GATA-3 is often primarily associated with Th2 cells, it is also expressed in a range of other cell types and is required for thymocyte development ([@B33]).

BCL-6 -- T-FOLLICULAR
=====================

During a T-dependent immune response CD4^+^ T cells are able to express the transcription factor BCL-6 that converts them to a PD-1^+^ CXCR5^+^ T-follicular helper subtype (Tfh; [@B12]). These cells then home to the follicle, due to the action of the chemokine receptor CXCR5 guided by CXCL13 produced by follicular stromal cells, and specialize in assisting B cell affinity maturation and memory cell formation within the germinal center ([@B12]). Recent work has demonstrated that thymically derived Tregs are also able to effectively mimic this phenotype by induction of BCL-6 giving a CXCR5^+^ PD-1^+^ phenotype that home to the follicular region. These cells appear to differentiate from thymically produced Tregs in response to the same SLAM-associated protein (SAP), CD28, and B cell-dependent signals that induce Tfh differentiation ([@B10]; [@B28]). This follicular Treg subset then travels to the germinal center and controls the germinal center reaction ([@B10]; [@B28]; [@B59]). At this time the primary suppression mechanisms used by follicular Tregs are not clear, although CTLA-4 protein levels and IL-10 mRNA expression is increased, while Granzyme B is reduced in comparison to normal Tregs ([@B28]). Surprisingly, given their expression of BCL-6, normally a mutual repressor of Blimp-1, these cells also express high levels of *prdm1* mRNA encoding the transcriptional repressor Blimp-1 ([@B10]; [@B28]) crucial to the expression of IL-10.

STAT3 AND RORγt -- Th17
=======================

The transcription factor STAT3 is essential for the proper development of Th17 cells ([@B30]). More recently a role for STAT3 in Treg biology has been demonstrated by the finding that STAT3-deficient Tregs are unable to prevent fatal Th17-mediated colitis ([@B8]). Interestingly, these Tregs retain *in vitro* suppressive capacity, presumably due to intact CTLA-4 function, but have reduced expression of IL-10, IL-35, and CCR6 ([@B8]). STAT3 phosphorylation by Tregs is induced in an IL-10-dependent manner with IL-10 receptor-deficient Tregs failing to phosphorylate STAT3 and restrain Th17 responses and the development of colitis ([@B9]). Additionally, IL-10 receptor (IL10R) expression by Th17 cells is critical for prevention of their inflammatory pathology ([@B24]).

A number of groups have reported that Tregs may be able to simultaneously express Foxp3 and the Th17 defining transcription factor RORγt, and may produce IL-17 ([@B63]; [@B50]; [@B23]). In humans, Tregs have been observed to lose suppressive function while producing IL-17 but then regain suppressive function, suggesting that this could be a temporary loss of suppressive capability in order to allow the immune response sufficient time to effectively fight pathogens before suppressive function is re-established ([@B2]). Interestingly, only CCR6-expressing Tregs expressed IL-17 ([@B2]). This is of relevance since CCR6 controls Treg accumulation at the sites of Th17-mediated inflammation due to the IL-17-mediated release of its ligand CCL20 by epithelial cells ([@B20]; [@B61]).

SYNTHESIS
=========

While all Tregs can be characterized as Foxp3^+^ CTLA-4^+^ and lacking IL-2 production, it seems that from this base state a range of transcription factors may be induced/co-opted in order to allow the Treg to adapt to inflammatory cues. It seems likely that Tregs share much of the same molecular machinery as conventional CD4^+^ T cells and thus respond to the same stimuli to differentiate into Thχ-like Tregs.

In this sense there is a core module of Treg suppression driven by Foxp3 expression that acts to prevent the activation, proliferation, and as a result the differentiation, of T-effector cells. This core module may be augmented by induction of additional modules, driven by transcription factors normally associated with other T cell subsets, allowing Tregs to adapt to become "Thχ-like" Tregs and deliver suppression to diverse sites within the body (**Figure [1](#F1){ref-type="fig"}**).

![**A two module model of Treg function.** Foxp3 acts to control the core module of Treg suppressive function by regulating expression of a number of key molecules such as CTLA-4 and CD25. This allows Tregs to suppress T-effector activation and proliferation by suppressing APC function via CTLA-4 and possibly depriving IL-2 from other T cells. An additional Thχ-like module of suppressive function may also be induced that causes Tregs to express Thχ-like transcription factors allowing the Tregs to take on some of the properties of Th1, Th2, Th17, or follicular T cells, travel to the same sites and deliver *in situ* suppression.](fimmu-03-00178-g001){#F1}

While the possibility that some Tregs may lose Foxp3 expression and become proinflammatory "ex-Tregs" is highly controversial ([@B64]; [@B36]; [@B21]; [@B31]), we should perhaps not be surprised to find some evidence of proinflammatory cytokine expression by Thχ-like Tregs that broadly retain suppressive function. While Foxp3 is a master regulator it does not totally repress the loci associated with Th1, Th2, and Th17 cytokines ([@B53]; [@B15]). As a result it is not necessarily a contradiction to find Tregs-expressing proinflammatory cytokines and it will be interesting to see if in some settings there are benefits to Treg expression of proinflammatory cytokines. For example, Treg expression of IFNγ has been reported in several settings; during infection with *Toxoplasma gondii* IFNγ-producing Tregs retained their *in vitro* suppressive capacity ([@B32]) while IL-12-induced IFNγ-producing Tregs retain both *in vitro* suppressive capacity and the ability to prevent colitis in an IFNγ-dependent manner ([@B16]). Treg produced IFNγ may also have a protective role in transplant tolerance. Alloreactive Tregs are able to prevent rejection of a BALB/c skin graft in C57/B6 mice, while Tregs from IFNγ-deficient mice were significantly less protective ([@B43]).

Thχ-like Tregs appear to have an effector Treg phenotype, with clear roles for IL-10 in STAT-3 and IRF4 driven suppression, while T-bet and BCL-6-expressing Tregs also seem to have upregulated expression of IL-10. While IL-10 is not critical to the *in vitro* function of Tregs ([@B48]; [@B37]), *in vivo*experiments have demonstrated IL-10 to be important in the maintenance of immune homeostasis in the gut, with IL-10-deficient mice spontaneously developing intestinal inflammation ([@B27]), while Treg-specific deletion of*il10*leads to colitis and inflammation at the lung surface ([@B37]), suggesting that its role may be to control excessive inflammation from microbial stimulation at mucosal surfaces rather than maintenance of self-tolerance. At this time it is not clear if the suppressive mechanisms employed by Thχ-like Tregs are different from previously defined effector Tregs, or if the differences are primarily due to cell localization. Additionally, it seems likely that, on close examination of their transcription factor expression, there may be substantial overlap between previously identified effector Tregs and Thχ-like Tregs. As it stands, no clear mechanisms of suppression that are truly specific to a particular Thχ-like Treg have been identified. As a result, it seems likely that these are specialized subsets of effector Tregs and the primary role of the induction of these transcription factors is to allow Tregs to respond to the same stimuli as conventional T cells, travel to the same sites, and enhance or upregulate existing effector Treg suppressive mechanisms such as CTLA-4 and IL-10.

CONCLUSION
==========

While Tregs have a core module of suppression driven by Foxp3 expression, they are also able to adapt to changes in their environment and harness additional modules by the expression of transcription factors normally associated with other T cell subtypes in order to better control immunopathology. Particularly in the light of ongoing work examining either transfer or depletion of Tregs in clinical settings it is critical that we understand both the core functions of Tregs and their range of flexibility that allows them to modulate their mechanisms of suppression and cell localization in response to specific stimuli.
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